The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 15, 2014
Filed:
Apr. 07, 2008
Masashi Suzuki, Ibaraki, JP;
Toru Imamura, Ibaraki, JP;
Yuriko Uehara, Ibaraki, JP;
Kaori Motomura, Ibaraki, JP;
Junko Oki, Ibaraki, JP;
Syuichi Oka, Ibaraki, JP;
Masahiro Asada, Ibaraki, JP;
Akiko Kuramochi, Ibaraki, JP;
Miho Kimura, Ibaraki, JP;
Masashi Suzuki, Ibaraki, JP;
Toru Imamura, Ibaraki, JP;
Yuriko Uehara, Ibaraki, JP;
Kaori Motomura, Ibaraki, JP;
Junko Oki, Ibaraki, JP;
Syuichi Oka, Ibaraki, JP;
Masahiro Asada, Ibaraki, JP;
Akiko Kuramochi, Ibaraki, JP;
Miho Kimura, Ibaraki, JP;
Abstract
Using betaKlotho or a substance that increases or inhibits betaKlotho activity as an agent for controlling the activity of FGF21 mediated by an FGF receptor, the present invention provides a pharmaceutical composition comprising such betaKlotho or such substance as an active ingredient, particularly, a pharmaceutical composition for anti-metabolic syndrome, and further particularly, a pharmaceutical composition for therapeutic or preventive use associated with the control of blood glucose level. In addition, the present invention provides a screening system for each of a substance that enhances or suppresses betaKlotho activity, an FGF21-like active substance, and a betaKlotho-like active substance, which uses a cell system that has expressed an FGF receptor and/or betaKlotho on the surface thereof.